Search in:

Advanced search

Expert Opinion on Pharmacotherapy Volume 9, 2008 - Issue 17

Submit an article Journal homepage

108

Views

CrossRef citations to date

Altmetric

Drug Evaluation

Managing neoplastic bone disease with ibandronic acid: a preclinical and clinical data update

Martin Pecherstorfer Hematologic-Oncologic Service, Landeklinikum Krems, Mitterweg 10, A-3500 Krems, Austria +43 2732 804 4425; +43 2732 804 6708; [email protected]

Pages 3111-3119 | Published online: 12 Nov 2008

Cite this article
https://doi.org/10.1517/14656560802482945

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Cameron D, Fallon M, Diel I. Ibandronate: its role in metastatic breast cancer. Oncologist 2006;11(suppl 1):27-33
PubMed Web of Science ®Google Scholar
Coleman RE. Bisphosphonates in breast cancer. Ann Oncol 2005;16:687-95
PubMed Web of Science ®Google Scholar
Gralow J. Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer. Clin Breast Cancer 2005;5(suppl 2):S54-62
Google Scholar
Van Poznak CH. The use of bisphosphonates in patients with breast cancer. Cancer Control 2002;9:480-9
PubMedGoogle Scholar
Brown JE, Neville-Webbe H, Coleman RE. The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer 2004;11:207-24
PubMed Web of Science ®Google Scholar
Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76
PubMed Web of Science ®Google Scholar
Finley RS. Bisphosphonates in the treatment of bone metastases. Semin Oncol 2002;29(suppl 4):132-8
PubMed Web of Science ®Google Scholar
Pecherstorfer M. Efficacy and safety of ibandronate in the treatment of neoplastic bone disease. Expert Opin Pharmacother 2004;5:2341-50
PubMed Web of Science ®Google Scholar
Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999;25:97-106
PubMed Web of Science ®Google Scholar
Russell RG. Bisphosphonates: from bench to bedside. Ann N Y Acad Sci 2006;1068:367-401
PubMed Web of Science ®Google Scholar
Roelofs AJ, Thompson K, Gordon S, et al. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006;12:s6222-30
PubMed Web of Science ®Google Scholar
Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics 2007;119(suppl 2):S150-62
PubMed Web of Science ®Google Scholar
Russell RG, Xia Z, Dunford JE, et al. Bisphosphonates: an update on how mechanisms of action relate to clinical efficacy. Ann N Y Acad Sci 2007;1117:209-57
PubMed Web of Science ®Google Scholar
Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88(suppl 12):2961-78
PubMedGoogle Scholar
Mühlbauer RC, Bauss F, Schenk R, et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991;6:1003-11
PubMed Web of Science ®Google Scholar
Pecherstorfer M, Herrmann Z, Body JJ, et al. Randomized Phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 1996;14:268-76
PubMed Web of Science ®Google Scholar
Ralston SH, Thiébaud D, Herrmann Z, et al. Dose–response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Br J Cancer 1997;75:295-300
PubMed Web of Science ®Google Scholar
Barrett J, Worth E, Bauss F, et al. Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 2004;44:951-65
PubMed Web of Science ®Google Scholar
Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003;14:1399-405
PubMed Web of Science ®Google Scholar
Body JJ, Diel IJ, Lichinitser MR, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled Phase III studies. Br J Cancer 2004a;90:1133-7
PubMed Web of Science ®Google Scholar
Bell R. Efficacy of ibandronate in metastatic bone disease: review of clinical data. The Oncologist 2005;10(suppl 1):8-13
PubMed Web of Science ®Google Scholar
Heras P, Karagiannis S, Kritikos K, et al. Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer. Eur J Cancer Care (Engl) 2007;16:539-42
PubMed Web of Science ®Google Scholar
Mystakidou K, Stathopoulou E, Parpa E, et al. Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease. Cancer Res Clin Oncol 2008 May 27 [Epub ahead of print]
PubMed Web of Science ®Google Scholar
Clemons M, Cole DE, Gainford MC. Can bone markers guide more effective treatment of bone metastases from breast cancer Breast Cancer Res Treat 2006;97:81-90
PubMed Web of Science ®Google Scholar
Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97:59-69
PubMed Web of Science ®Google Scholar
Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23:4925-35
PubMed Web of Science ®Google Scholar
Body JJ, Lichinitser M, Tjulandin S, et al. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases. Ann Oncol 2007;18:1165-71
PubMed Web of Science ®Google Scholar
Paterson AHG. The role of bisphosphonates in early breast cancer. Oncologist 2006;11(suppl 1):13-9
PubMed Web of Science ®Google Scholar
Rivkin S. Oral ibandronate versus intravenous zoledronic acid for breast cancer patients with skeletal complications: the SWOG trial. Bone 2006;38(suppl 1):S82
Web of Science ®Google Scholar
Vassiliou V, Kalogeropoulou C, Christopoulos C, et al. Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment. Int J Radiat Oncol Biol Phys 2007;67(1):264-72
PubMed Web of Science ®Google Scholar
Bell R, Diel IJ, Body JJ, Bergström B. Renal safety of ibandronate in patients with bone metastases from breast cancer: Phase III trial results. Eur J Cancer Suppl 2004;2:132
Web of Science ®Google Scholar
Body JJ, Diel IJ, Bell R, et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004;111:306-12
PubMed Web of Science ®Google Scholar
Diel IJ, Body JJ, Bergström B. Low nephrotoxicity of ibandronate: implications for the management of patients with metastatic bone disease. Support Care Cancer 2004;12:406-7
Google Scholar
Clemons M, Dranitsaris G, Ooi W, et al. A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. Breast Cancer Res Treat 2008;108:79-85
PubMed Web of Science ®Google Scholar
Mancini I, Dumon JC, Body JJ. Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol 2004;22:3587-92
PubMed Web of Science ®Google Scholar
Heidenreich A, Elert A, Hofmann R. Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 2002;5:231-5
PubMed Web of Science ®Google Scholar
Heidenreich A, Ohlmann C, Olbert P, et al. High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer. Eur J Cancer 2003;1(suppl 5):S270
Google Scholar
Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000;60:2949-54
PubMed Web of Science ®Google Scholar
Hiraga T, Williams PJ, Mundy GR, et al. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 2001;61:4418-24
PubMed Web of Science ®Google Scholar
Neudert M, Fischer C, Krempien B, et al. Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterisation and in vivo effects of ibandronate on tumour growth. Int J Cancer 2003;107:468-77
PubMed Web of Science ®Google Scholar
Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62:6538-44
PubMed Web of Science ®Google Scholar
Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro J Bone Miner Res 2000;15:2211-21
PubMed Web of Science ®Google Scholar
Magnetto S, Boissier S, Delmas PD, Clézardin P. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer 1999;83:263-9
PubMed Web of Science ®Google Scholar
Journe F, Chaboteaux C, Magne N, et al. Additive growth inhibitory effects of ibandronate and antioestrogens in oestrogen receptor-positive breast cancer cell lines. Breast Cancer Res 2006;8:R2
PubMed Web of Science ®Google Scholar
Cartenì G, Bordonaro R, Giotta F, et al. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial. Oncologist 2006;11:841-8
PubMed Web of Science ®Google Scholar
Gordon DH. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, Phase III trials. Clin Breast Cancer 2005;6:125-31
PubMedGoogle Scholar
Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006;17:897-907
PubMed Web of Science ®Google Scholar
Coxon FP, Thompson K, Rogers MJ. Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 2006;6:307-12
PubMed Web of Science ®Google Scholar
Bergström B, Lichinitser M, Body JJ. Intravenous and oral ibandronate have better safety and tolerability profiles than zoledronic acid: evidence from comparative Phase II/III trials. Bone 2006;38(suppl 1):S68
Web of Science ®Google Scholar
Bobba RS, Beattie K, Parkinson B, et al. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. Drug Saf 2006;29:1133-52
PubMed Web of Science ®Google Scholar
Aapro M, Abrahansson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Annals Oncol 2008;19:1407-16
PubMed Web of Science ®Google Scholar
Mason MD, Sydes MR, Glaholm J, et al. Oral sodium clodronate for nonmetastatic prostate cancer – results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst 2007;99:765-76
PubMedGoogle Scholar
Suri S, Mönkkönen J, Taskinen M, et al. Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. Bone 2001;29:336-43
PubMed Web of Science ®Google Scholar
Diener KM. Bisphosphonates for controlling pain from metastatic bone disease. Am J Health Syst Pharm 1996;53:1917-27
PubMed Web of Science ®Google Scholar
von Moos R. Bisphosphonate treatment recommendations for oncologists. Oncologist 2005;10(suppl 1):19-24
PubMed Web of Science ®Google Scholar
McLachlan SA, Cameron D, Murray R, et al. Safety of oral ibandronate in the treatment of bone metastases from breast cancer: long-term follow-up experience. Clin Drug Investig 2006;26:43-8
PubMed Web of Science ®Google Scholar
Munier A, Gras V, Andrejak M, et al. Zoledronic acid and renal toxicity: data from French adverse effect reporting database. Ann Pharmacother 2005;39:1194-7
PubMed Web of Science ®Google Scholar
Oh WK, Proctor K, Nakabayashi M, et al. The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer 2007;109:1090-6
PubMed Web of Science ®Google Scholar
Bergner R, Diel IJ, Henrich D, et al. Differences in the nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease. Onkologie 2006;29:534-40
PubMedGoogle Scholar
De Lemos ML, Taylor SC, Barnett JB, et al. Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database. J Oncol Pharm Pract 2006;12:193-9
PubMedGoogle Scholar
Body JJ, Diel IJ, Tripathy D, Bergström B: Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: Phase III trial results. Eur J Cancer Care (Engl) 2006;15:299-302
PubMed Web of Science ®Google Scholar
Pecherstorfer M, Rivkin S, Body JJ, et al. Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial. Clin Drug Investig 2006;26:315-22
PubMed Web of Science ®Google Scholar
Pfister T, Atzpodien E, Bauss F. The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicol 2003;191:159-67
PubMed Web of Science ®Google Scholar
Pfister T. Comparative renal effects of two intravenously administered bisphosphonates. Toxicol 2004;196:169-70
Web of Science ®Google Scholar
Kiagia M, Karapanagiotou E, Charpidou A, et al. Rapid infusion of ibandronate in lung cancer patients with bone metastases. Anticancer Res 2006;26:3133-6
PubMed Web of Science ®Google Scholar
von Moos R, Thürlimann B, Caspar CB, et al. Renal safety of intravenous ibandronate 6mg infused over 15 or 60 minutes in patients with breast cancer and bone metastases: a randomized, open-label study. J Clin Oncol 2007;25(18S):1114
PubMed Web of Science ®Google Scholar
Body JJ, Coleman R, Clezardin P, et al. International Society of Geriatric Oncology. International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur J Cancer 2007b;43:852-8
PubMed Web of Science ®Google Scholar
Body JJ. Safety and tolerability of bisphosphonates in the elderly: objective data. Presented at the 6th Meeting of ISGO/SIOG, Geneva; 2005
Google Scholar
Henrich D, Hoffman M, Uppenkamp M, et al. Ibandronate for the treatment of hypercalcemia or nephrocalcemia in patients with multiple myeloma and acute renal failure: case reports. Acta Haematol 2006;116:165-72
PubMed Web of Science ®Google Scholar
Bergner R, Henrich DM, Hoffman M. Renal safety and pharmacokinetics of ibandronic acid in multiple myeloma patients with or without impaired renal function. J Clin Pharmacol 2007;47:942-50
PubMed Web of Science ®Google Scholar
Krueger CD, West PM, Sargent M, et al. Bisphosphonate-induced osteonecrosis of the jaw. Ann Pharmacother 2007;41:276-84
PubMed Web of Science ®Google Scholar
Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 2006;134:620-3
PubMed Web of Science ®Google Scholar
Body JJ. Breast cancer: bisphosphonate therapy for metastatic bone disease. Clin Cancer Res 2006;12:s6258-63
Web of Science ®Google Scholar
Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-7
PubMed Web of Science ®Google Scholar
Aguiar Bujanda D, Bohn Sarmiento U, Cabrera Suárez MA, Aguiar Morales J. Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis. Ann Oncol 2007;18:556-60
PubMed Web of Science ®Google Scholar
Guarneri V, Donati S, Nicolini M, et al. Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years. Oncologist 2005;10:842-8
PubMed Web of Science ®Google Scholar
Tassinari D, Poggi B, Nicoletti S, et al. Zoledronic acid treatment at home: safety data from an observational prospective trial. J Palliat Med 2007;10:352-8
PubMed Web of Science ®Google Scholar
Corso A, Varettoni M, Zappasodi P, et al. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leuk 2007;21:1545-8
PubMed Web of Science ®Google Scholar
Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006;91:968-71
PubMed Web of Science ®Google Scholar
Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 2006;7:508-14
PubMed Web of Science ®Google Scholar
Mystakidou K, Katsouda E, Stathopoulou E, et al. Approaches to managing bone metastases from breast cancer: the role of bisphosphonates. Cancer Treat Rev 2005;31:303-11
PubMed Web of Science ®Google Scholar
De Cock E, Hutton J, Canney P, et al. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom. Clin Ther 2005;27:1295-310
PubMed Web of Science ®Google Scholar
De Cock E, Hutton J, Canney P, et al. Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. Support Care Cancer 2005;13:975-86
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Managing neoplastic bone disease with ibandronic acid: a preclinical and clinical data update

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Managing neoplastic bone disease with ibandronic acid: a preclinical and clinical data update

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date